Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 vs 7 Days Ceftriaxone Prophylaxis in Acute Variceal Bleeding
NCT00838864Phase 4Completed
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Mar 2009
- Primary completion
- Mar 2013
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone in Gastrointestinal Bleeding (GIB), esophageal varices and gastric varices (2 arms), sponsored by Far Eastern Memorial Hospital. Primary endpoint: Rebleeding rate within 14 days. Started Mar 2009; status: completed.
02
Drugs
ceftriaxone
03
Conditions
Gastrointestinal Bleeding (GIB)esophageal varicesgastric varices
Beyond the preview
Go deeper on NCT00838864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838864.